Future Proofing Medical Affairs: A Conversation with Stephanie Hunter Banks In this episode of Pharma Sessions, host Jonathan Kaskey speaks with Stephanie Hunter-Banks about the future of the medical science liaison (MSL) role and the evolving healthcare ecosystem. Stephanie shares insights on creating a culture of innovation, leveraging big data and AI, and fostering collaboration within pharma companies. She reflects on her own career journey from pharmacy to leading learning ... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_01Culture matters at the company. So creating a culture where failure and exploration are something that is acceptable is going to be key. I think you have to get buy-in at the most senior levels first because most companies are reticent to go outside of what we've traditionally seen as medical affairs. But we can't continue to be that way because the healthcare ecosystem is changing.
SPEAKER_00Hello, hello, and welcome to PharmaSessions, the podcast where Metafares professionals come to learn from each other. I'm your host, Jonathan Kaskey. I had a fascinating conversation with Stephanie Hunter Banks. We explored how to future-proof the role of the medical science liaison and the innovations transforming the healthcare ecosystem. From leveraging big data and AI to creating a culture that fosters innovation and collaboration. There's a ton of great stuff in this episode.
SPEAKER_00As always, the views here are mine and Stephanie's and don't reflect those of our employers. So without further delay, let's dive in.
SPEAKER_01So I'm a pharmacist by training. I've always loved healthcare and giving back. And so I went into pharmacy thinking that I would be boots on the ground in the community working at clinics and things like that directly with patients and families. I ended up doing a specialty residency and drug information, which led me to go into industry. And going into industry really was a decision that I made to be able to have a broader impact on the populations that I was serving in those capacities.
SPEAKER_01And so I went into industry as a drug information specialist, or right now we call it medical information, with the intent of really learning about pharma. Didn't really have a plan on where I wanted to go. But when I got there, obviously I had lots of opportunity to interact with different people. One of them happened to be, of course, the medical director role, which I worked really closely with in our PRC or promotional review committee activities. And at the time where I worked, we didn't have a field medical or MSL team.
SPEAKER_01And just like most other companies, we were beginning to start to build those out. And they decided at that time that we would be called health science advisors. So I decided to transition to the medical science liaison role, not because I was going, ooh, I want to be an MSL, but it really posed an opportunity for me to move back to sunny South Florida from Ohio. And I went into it eyes wide open, thinking, I don't know what this job is, but I know I'm going to make it great and I love it. And so I was in MSL for around 10 years.
SPEAKER_01And during that time, I did a lot of special projects, did a lot of training, and decided that for me, it harkened me back to residency time when I was teaching, that I really enjoyed interacting with students. I really enjoyed the learning process for adults and decided to really transition my career into learning and development. And I took a job working as associate director of MSL development, which morphed into many different things over 10 years. I've done operations, compliance, but and I also worked in commercial for three years, leading a team that focused on HCP and stakeholder engagement.
SPEAKER_01And then came back to my love of LD. And now I lead a learning and development team specifically designed to support learners and enable our colleagues within medical affairs. So that's 25 years condensed into a couple of minutes.
SPEAKER_00That was really impressive to be able to take those decades and get them down like that. But I'm just curious, that's do you find it's helpful having been in NSL when you go and you're working on NSL development and leading, leading L and D? Do you feel like you can have different conversations with people that if you've been in the background?
SPEAKER_01Absolutely. Because there's a job description that you read. It talks about high-level scientific exchange and being able to engage in work that helps clinicians and providers better understand the evidence. And then there's the actual job itself. And so I think having an understanding of the ebb and flow of life cycle management of a compound and what that looks like from a field medical support or field medical engagement standpoint, having that experience helps me to put a lot of things in context for other folks as well.
SPEAKER_01And to start to think outside of the box, especially since post-COVID, in terms of how we continue to evolve the role so that it continues to provide the value that most organizations see in it. And I think being an MSL and having that experience where I can come in and say, this is what, this is what the day-to-day looks like. And here's some recommendations, it adds a lot more credibility, especially when you're doing things like writing scenarios for learning and development curricula or events or solutions.
SPEAKER_01It helps a lot to be able to bring that context. So yes, I do think it has helped me.
SPEAKER_00You're right. I'm sure you have a whole library of your visits from back in the day when it's I'm fully trained up, I'm ready, I got my whole pitch planned and then or my whole talk track planned, and then I hit Miami traffic or my gosh.
SPEAKER_01If you were and you end up running from running from the parking back of the parking lot into the office and trying to get the stories I could tell, I started in the pre-what we call pre-pharmacode days, and the MSL role at the time was a medical role, but we had a lot of collaboration with our commercial colleagues. We still maintained our integrity and uh the value that we bring, being separate from them. But there were things, so for example, the commercial team could do what we call gas and goes, or I wouldn't call them gas and goes.
SPEAKER_01They're called like uh lunch and learn gas and goes. People could come and learn about your product, but then they get something in return. And where I work, one of the requirements for the reps to be able to do that was to have a medical science liaison present to be able to answer any questions that scientific questions that came up. And so I that was back in the day, so to speak. But there's a lot that goes into being an MSL beyond just knowing the data.
SPEAKER_00That's fascinating. So today, what we're talking about is transitioning the MSL organizations into the future. And a lot of what when we were pre prepping for the episode, what we talked about was systems and integrating data and tech. But I'm just curious, before you even get into any of that big data or AI stuff or whatever, what do you think an environment needs to look like at a pharma company so that there's allowances for that type of innovation?
SPEAKER_01Yeah, I think that culture matters at the company. So creating a culture where failure and exploration are something that is acceptable is going to be key. The other thing is creating an environment where there's a lot of collaboration, right? A lot of times in medical affairs, we don't go down certain or explore certain avenues of the work that we do because people say we can't do that because we're medical. And I think it's important to build environments that allow for the co-creation or at least the brainstorming of ideas so that we can forge a way forward together versus immediately falling into a road roadblock and using what I call the classic, we can't do that because we're medical affairs as a get out of jail free card.
SPEAKER_01Organizations that empower people to think outside the box and then do what I call the iterative approach of agile, which is test, uh, learn, retest, apply, test, learn, retest, apply. If you go through that cycle, you'll ultimately end up with something probably more likely to be more innovative, um, more likely to produce solutions that really drive a lot of value for patients. But if we only continue to operate in our silos, then the magnitude of impact that we'll be able to drive as an or as as individual organizations, but really even as a collective industry, we won't ever reach our full potential because we're not taking into consideration the possibilities.
SPEAKER_01And so I think organizations that allow for that and that are okay with piloting new things to learn and then figuring out what does that look like if we scale it, if you take that kind of approach, then you'll probably come up with new ideas and different ways to do things. And that's that's what I think organizations need to lean a little bit more into.
SPEAKER_00And then how I'm trying to think of the right way to word this, but how deep into the organization does that need to go? So you mentioned agile, uh, which I'm familiar with from a software development framework, right? Or or that type of thing. And it's something that in a lot of software companies, it's just you know what people are talking about when they're talking about agile and the test and learn retest applied, that that makes sense too, right? And you're trying to figure out what am I actually testing for? Does my test for the right thing or whatever?
SPEAKER_00But I'm wondering if outside of that world and outside of like the general change management or L D D world, like the when you start if do you actually use words like agile when you're talking with your MSL organizations or your medical directors, or are you trying to reframe it in other ways? How are how deep do you need the buy-in to be for creating this innovative environment?
SPEAKER_01No, I don't think you have to use the terminology agile. I think if you use the words curiosity, iterative approach, piloting new things, people get the gist, and you can put a process frame around that. You don't necessarily have to use that language. And I think just creating space for MSLs who are out there every day in the field to bring in insights, new ways of working, ideas in different populations, for example, that they think we might be able to support or to provide education or scientific information to.
SPEAKER_01I think creating the space for them to say, hey, this is an opportunity. And I think if we were to organize in this way or to collaborate in this way, um, we may be able to uh drive additional medical value. But you have to create the opportunity for that conversation to happen. And it doesn't necessarily need to go down deep because once you go down deep, you really just have to have the process, right? Of here's what it looks like, here are the rules of the road. I think you have to get buy-in at the most senior levels first, because most companies are reticent to go outside of what we've traditionally seen as medical affairs.
SPEAKER_01And I think, but we can't continue to be that way because the healthcare ecosystem is changing. And if we don't think about new ways, because there's new people that are involved in decision making, there are new people that are involved in healthcare management. And unless we figure out ways to engage them as well, again, like I said, we're leaving things on the table that we otherwise could have provided some value for and perhaps driven different outcomes because of it.
SPEAKER_00So it's like from the executive level, you want to create an environment where the default answer isn't no. Right. And or isn't that's just the way we've we've done it, or that's not our that's opening up an environment that allows for more of that experimentation or that creativity. And then I th I like what you said at the beginning, where failure is okay, right? We're gonna try something new. And if it doesn't work out perfectly the first time, that's okay, right? Because we might do it, we might continue it, we might drop it all together, we might do it a little differently, but it's not the end of the world.
SPEAKER_00Is that a big ask for is that a big change from how most pharma companies operate or most medical affair companies are already operating?
SPEAKER_01I think it is because we're most of the time when you look at the profile of people that are in medical affairs or that in pharma in general, right? We're all type A type of folks, right? Where most of these people are highly successful in our group, everyone has a terminal degree. So think about the grit, resilience, and focus it takes to get a doctorate degree. And yeah, I think that getting people to shift from one way of thinking to go from that to something different takes a little bit of effort, but I think it's doable.
SPEAKER_00This episode is sponsored by Structured Meetings. It's a Teams app that turns your own Teams incidents into the perfect advisory board platform. Save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com. So do you have any one of the things that's always important when you're trying to get people to do something is probably like, why do I want to do this? Do you have any examples of companies that have maybe opened themselves up for innovation in medical and some of the things that they've achieved or that's different?
SPEAKER_00What's the why behind to opening yourself up for these new ways or this new risk?
SPEAKER_01Oh, because I think there's okay, so there's things, if I look specifically about on if I just take, for example, enrollment in clinical trials, which I'm pretty sure we're going to get to a whole discussion on how we use data digital maybe to perhaps accelerate that. But if you think about enrollment in clinical trials, a lot of times right now, the way our model is set up, it's like you go through the safety trials first. Obviously, you identify the compound, look at potential pathways and come up with your target patient profile.
SPEAKER_01But then after that, you have to enroll in clinical trials for both safety. But when you get to phase three and you have to look at efficacy and safety, enrolling in clinical trials when there's competition can be difficult, right? So as you look at the medical science liaison role, is are there data sets that help us identify, for example, where potential populations or untapped populations might be that may actually benefit from participation in a clinical trial, but otherwise may not know about it because maybe they're in a rural area and don't the closest tertiary care center is four hours away?
SPEAKER_01Or maybe there's a trust issue there with participating in clinical trials. What if we could engage with our medical science leads on team to identify based on data, right? Looking at geographic data for diagnoses that are happening. What about comorbidities if we wanted to exclude things or include things, for example? Could we map that out and basically do a geographical data visualization of where those potential investigators might be, and then identify who they are and in a targeted specific way, engage our MSOs to go out and start to have dialogue about the company and thinking about how we run our clinical trials and perhaps becoming an investigator.
SPEAKER_01That could lead to or accelerate milestones in a clinical trial, which then at the end of the day, it harkens the time that it takes to actually get the data back to go to FDA for approval and hence the day, the access to the medication. That's just one example of how we could leverage the medical science leads on team in a different way. Now, I think being able to do things like that really start with conversations about where do we see medical affairs adding the most value and really thinking outside the box from traditional thought around just it being a focus on scientific change and transitioning from that to more of a dialogue.
SPEAKER_01And dialogue requires two-way, right? It's a give and take. You receive something, but you're also giving something. And in order to do that, though, you have to start to look and say, okay, where are the greatest unmet needs, right? And how can we as a pharma company help support this population where they are? But then you have to understand a little bit more about the population, right? So it needs to be a conversation that almost like maybe whiteboarding it out to start to uncover where you have those opportunities.
SPEAKER_01And then for each one of those opportunities, make a decision about whether or not that's a space that you feel like medical affairs can really make a difference. And if the answer is yes, then deep dive into what that could look like. And that's how you get to innovation. That's how you get to doing new things. Now, I haven't worked at all the pharma companies in America, but I can just tell you that in general, most pharma companies are erring on the side of caution. Um, because anything that is viewed as being promotional or influencing for the wrong reasons, physicians or providers, it's not something that we do in medical affairs.
SPEAKER_01And so there's a lot of hesitation to do things potentially, right, that could be seen in that way. But if we're going to change medical affairs, we're going to have to be the ones to change it. FDA is not going to come along and say, hey, we're innovating over here at FDA. And here's some new things that we see medical affairs can do. We will have to create what that opportunity looked like and then bring all the stakeholders together around the table to say, we want to evolve how we view medical affairs. And here's here are the areas that we think medical affairs can add value and make a difference as a collective, or even if you want to start with your individual company, that's where it all starts anyway.
SPEAKER_01It's grassroots. Start those conversations at your own company and then find forums and opportunities to share best practices so that other organizations may want to test out what you guys have tried and either succeeded or continuing to grow on. So yeah, I could go on and on about that topic.
SPEAKER_00No, it's really interesting, and to me, the story that you gave seems incredibly plausible. Using all these different data sets, whether it's claims data or diagnostic data or whatever, to identify patient populations that for whatever reason weren't being identified or their potential trial participants in this case. But it that that seems to me within the remit of Bed Affairs, because if you can do that, ultimately you're driving patient care, right? You're helping get a drug to market faster to solve people's problems, or you're getting the right people enrolled in in the trial.
SPEAKER_00It doesn't, to me anyway, it doesn't sound terribly out out of pocket. I guess what is it the idea of accessing different types of data sets that is a little squishy for people? Or if some of that maybe some of that is like prescription data or something like that. Is that where people tend to get turned off by it?
SPEAKER_01Yeah, I think there are data that are readily available to us because we have the ICD 10 codes, so we can look at things like diagnosis codes. But then there are internal, there are um open access data around patient reported outcomes that can also be helpful. There are Z-score or Z codes that are have been implemented and integrated into health record systems. Now, whether or not they're being utilized to the greatest extent possible, the answer is probably no. But they look at social determinants of health. And I think the collective aggregation of all of these data can give us signals that tell us where we may want to focus our time, effort, and energy for specific disease states.
SPEAKER_01But we're collecting data right now en masse. And it's only going to get, we're only going to continue to collect more, right? So the pool of data that we'll have access to is just going to grow. Whether or not, whether or not we need to look at prescription data, I don't think that's the right data set. But if we're looking at health economic data, if we're looking at outcomes research, if we're looking at patient-reported outcomes, if we're looking at health-related data specific to things like social needs for people in that population or social determinants of health, then within those broad data sets, and if I also include medical science liaisons, bringing insights back to an organization and organizing that in a way that it goes into a data lake that can be analyzed and the information can be evaluated to surface new things that in concert with other data sets might tell you something.
SPEAKER_01But right now, we really are looking at it in a way that is more siloed, right? Our HUR teams are looking at their data sets. Our commercial teams have access to their data sets. Our market research, for example, market research can tell you a lot about subscriber behavior and what goes into the decision when they make a decision to prescribe a new drug. You could also learn what goes into a patient's decision to be compliant with that new drug, right? Are there things that we can learn that translate back to the science that medical can then drive?
SPEAKER_01But if we're only tapping into a portion of that, certainly we still have some opportunities there. Yeah.
SPEAKER_00Yeah. And it's with all of this data, because I think you're 100% right. There's just there's so much, it's so complicated, and there's more and more coming. It almost seems like in an MSL five years from now might pull up at a a doctor's office and they pull open their phone, and it's this patient population this doctor serves the following this patient population, they're more. concerned about access than anything else. And by the way, um they'd be a good uh this doctor might be a good uh candidate um to enroll some of their patients in the trial because of X, Y, and Z.
SPEAKER_00And then they go someplace else and they open their phone and they see a completely different framework. And then when they go to report the outcomes, maybe there's some guidance. How are we taking the information you're doing and we're getting it into our CRM in a way that allows us to search for through it in the right way? Has all that already started happening or is that still being developed in the organizations that that you're working out about truly enabling these people, the MSLs, as they're seeing doctors?
SPEAKER_01So there's a couple of things. I think that some organizations are further along than others in terms of being able to integrate. Now do I think people have looked at CRMs? Yes, we probably all use around the same CRM and the CRM capabilities are incredible, right? You can look at within presentations and see whether or not people have high, medium or low, for example, sentiment related to specific concepts that you're presenting. You could also leverage the data that is being input as text into a system and use Latin natural language processing to surface themes within that text.
SPEAKER_01So those things are already happening. I think there's two pieces to it it is identifying the right tools and data analytics approaches that help us to get better at putting big sets, big sets of data into data lakes so that they can be evaluated. The other piece to that, there's probably three pieces the other piece to it is around how do we train our teams to be able to use the information. So there's a piece around digital literacy that we need to catch the teams up on because if we're showing different views of data, they need to be able to interpret and understand what that means as they're making decisions in their geography or in their territory or what kinds of things could we be talking about here?
SPEAKER_01Could we look at connections between provider groups or stakeholders? Could we look at things like insurance coverage in a specific geography to help physicians understand what their population looks like could we also the data literacy or digital literacy piece is important because as soon as you put a system in place that can do that analysis, it's going to give you some a report and being able to interpret it, data's only good is is the interpretation or people being able to use it.
SPEAKER_01So making sure that the teams are equipped to use it is going to be key. And then the other big elephant in the room is around artificial intelligence and how do we leverage AI to be more efficient in the work that we do. And I think we're just scratching the tip of the iceberg here when it comes to AI because most organizations have implemented some type of AI or personal assistant tool. Most people have tried it out I wouldn't say most let me just say people that are early adopters of tech and are into it probably have already tried it out and seeing that wow I could expedite some of my work I could get a meeting summary and make sure that I'm covering off on the topics that we talked about in terms of next steps and make sure that I get that quickly out to the stakeholder that I just met with five minutes ago.
SPEAKER_01Maybe the computer could do that as I'm on the plane back home. So there I can imagine things like going to scientific meetings and congresses and while people might will likely still be there, the interactivity between the humans that are there and the content in a digital space is just going to grow, right? There may be AI that might say within this data set, tell me what the outcome would have been predictive analytics could have been if we exclude for these factors or the opposite, if we include these additional factors, right?
SPEAKER_01Because most clinical trials in the way that we design them today are what I call clean populations. They're representative in a ways that show if this drug is going to, there's if efficacy does the drug actually work but when we get to the effectiveness of the drug which is different it you can look at that in the population based on most people will have some level of comorbidity that we hadn't evaluated in a clinical trial. We start collecting that data we already collect postmarketing surveillance on safety but think about what that could look like when it comes to outcomes and how that could inform either new populations or specific ways to dose or specific um approaches to minimizing side effects so you improve compliance.
SPEAKER_01So those are just some of the examples things like artificial intelligence tools can be used to help us with in the future we're not there yet though, trust me.
SPEAKER_00Wow yeah but I'm sure most companies are in one way or another trying interested in AI and trying to get you know get their teams as far as dance as they can now absolutely if you think of with your background in learning yeah I think about something like medical communications right what if I and this actually does exist so what if you could upload the clinical study report and ask the AI to give you an executive summary of 20 slides of that report.
SPEAKER_01It probably could do it in less time it takes for you to blink your eyes five times and I'm not saying that it's the end all be all but what it does is give you a starting point. And the more it learns the um better it will be and the more accurate it'll be so again like I and if I take it one step further and go, what about data visualizations on this on some of our scientific uh studies what if the person doesn't want to see it in a slide in a slide maybe they want to see a visual maybe you can tell it hey AI take this slide and give me four visuals that represent this data to talk through because you know the KOL or the HCP likes to receive data in a more visual way.
SPEAKER_01In the future you may be able to do that based on some of the integrations of AI into the platforms that we have today and even new ones that'll probably be developed.
SPEAKER_00That's fascinating and it's also I think a lot of times people are scared when you start talking about AI I don't want a robot taking my job but what you're describing is not that what you're describing is you using the I'm using robot for AI, you using the robot to help you do your job better and more effectively.
SPEAKER_01Yeah I don't think we'll ever get away from the relational part of medical affairs, especially field medical there's a reason why we're human beings. We like to interact with each other. Computers and all of these tools make our lives hopefully better, more efficient, we can do things faster so that we can spend more time with each other. I think that was the initial intention behind some of these things. And I just don't think that given our space in healthcare is a personal space discovering and studying new medicines is a personal space.
SPEAKER_01So getting and a lot of the innovation doesn't come because someone's in a lab by themselves in the basement somewhere singularly with their computer. There's a reason why there are teams working on things there's research assistance there's this human aspect of really pressure testing and coming up with new ideas and the tools that we have today are great, but we will do we will be able to do that in a much more efficient, much more impactful way in the very near future.
SPEAKER_01You saw it with the development of the COVID 19 vaccine right it was a collaboration of many scientists around the world to get that into a space and then using data as well to accelerate what the anticipated side effects are now we can figure out how to mitigate them through dosing, get the right dose let's test it and see what happens. So you're able to accelerate access to things we proved that concept during the pandemic and now we just take what we learn and apply it to different areas that we're currently working in in our industry.
SPEAKER_00I love that and since we're talking about future state let's end on our an optimistic question here. But um so so this is one I always like to ask people but what are you most excited about given what you're seeing in medical affairs for the future of medical affairs?
SPEAKER_01Wow I think the thing that I'm most excited about is that medical affairs will finally accept its position as a leader within our industry. I think when I first started out we always use the word support like you're a support function and I don't see us being that I think we will because we will be able to interpret all of these different uh data assets and bring them to a specific strategy for example for the organization or at least inform that in a different way I am very optimistic about medical affairs being the leader in our industry, driving how we bring value to patients because again most of the people either come from a science background or are former clinicians and we do have people in our industry that still practice by the way as well and bringing that knowledge bringing those experiences into the organization in such a way that helps to inform strategy is where I think I get really excited when I think about that because for a you know a lot of times we have a seat at the table.
SPEAKER_01Most organizations are very much collaborative in terms of including medical affairs. But I think we would have more input and influence over the decisions that are being made based on the insights that we can bring back to the organization. I'm really excited about organization or our field medical teams being able to do that. I'm also very excited about the possibility of thinking of different stakeholder groups, population health specialists, perhaps people that do clinical research and having clinical research liaisons, thinking about medication therapy management programs that most insurance providers offer to patients and how we could inform the efficacy or I should say the efficacy the effectiveness of those programs.
SPEAKER_01At the end of the day, I think we have a unique opportunity to improve self-efficacy and self-management and thereby improve outcomes for our patients by taking on more of a leadership role. And so that's what excites me because I know that we're right there. I've seen it over and over again and I think that it's not to say that one group is better than the other because certainly that's not what I'm saying. What I'm saying is that the depth of value that we can bring to organizations is going to grow because we'll be able to do the data analysis in ways that think about I hate to say the business but really the business so that the business and why we do what we do on behalf of patients, they always align and we're there to make sure that happens.
SPEAKER_01So again I'm really excited about that. That's fantastic.
SPEAKER_00All right so let's leave it there Stephanie and I will just say thank you for joining me thank you so much. Thank you. This episode is sponsored by Structured Meetings. For listeners who don't know my background I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards and not to brag but my clients did more events than anyone else's. I've literally led thousands from the vendor side so I can humbly claim some expertise. One of the questions I used to get all the time was can we just do this in Teams?
SPEAKER_00And the answer back then was not really Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own Teams instance. It changes Teams just enough to check all the boxes for what's needed for great ad boards. And also it's super fast and it saves people a ton of money. Visit www dot structuredmeetings dot com for more info. All right, back to the show
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...
In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...
Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...
What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...
What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...